HomeMarket News Vertex Unit ViaCyte Opts Out of...

Vertex Unit ViaCyte Opts Out of CRISPR Diabetes Program Vertex Pharmaceuticals’ Subsidiary ViaCyte Takes Exit Cue from CRISPR’s Diabetes Program

Actionable Trade Ideas

always free

Molecule of DNA forming inside the test tube equipment.3d rendering,conceptual image.

undefined

On Monday, CRISPR Therapeutics (NASDAQ:CRSP) made known that Vertex Pharmaceuticals (VRTX) cohort ViaCyte has decided to bow out of their collaborative venture focused on gene-edited stem cell therapies tailored for diabetes treatment.

The consequence of this move is that the assets under the partnership, including CTX211, will now be entirely possessed by CRISPR. Nevertheless, ViaCyte is entitled to a royalty on future product sales. CRISPR has committed to pushing forward with the Phase 1 trial for CTX211, targeting the treatment of type 1 diabetes.

CRISPR has reported that the opt-out will come into effect at the beginning of February.

Vertex will retain rights to specific CRISPR/Cas 9 technology for the potential development of curative therapies for type 1 diabetes, as stated by CRISPR. Vertex has already disbursed $170M to CRISPR under their agreement, with CRISPR positioned to receive an additional $160M in R&D milestone payments and future royalties on products.

The biotech company marked the commencement of 2024 with $1.9B in cash and equivalents, inclusive of a $200M milestone payment linked to the FDA approval of the sick cell disease therapy Casgevy, developed in collaboration with Vertex.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.